Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates

被引：211

作者：

Henderson, S. J. ^{[1
]}

Konkar, A. ^{[2
]}

Hornigold, D. C. ^{[1
]}

Trevaskis, J. L. ^{[2
]}

Jackson, R. ^{[1
]}

Fritsch Fredin, M. ^{[3
]}

Jansson-Loefmark, R. ^{[3
]}

Naylor, J. ^{[1
]}

Rossi, A. ^{[1
]}

Bednarek, M. A. ^{[1
]}

Bhagroo, N. ^{[2
]}

Salari, H. ^{[2
]}

Will, S. ^{[2
]}

Oldham, S. ^{[2
]}

Hansen, G. ^{[4
]}

Feigh, M. ^{[4
]}

Klein, T. ^{[4
]}

Grimsby, J. ^{[2
]}

Maguire, S. ^{[1
]}

Jermutus, L. ^{[1
]}

Rondinone, C. M. ^{[2
]}

Coghlan, M. P. ^{[1
]}

机构：

[1] MedImmune Ltd, Cambridge, England

[2] MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 USA

[3] AstraZeneca R&D, Molndal, Sweden

[4] Gubra ApS, Horsholm, Denmark

来源：

DIABETES OBESITY & METABOLISM | 2016年 / 18卷 / 12期

关键词：

bodyweight; cynomolgus monkeys; diet-induced obese mice; dual agonist; GLP-1 receptor knock-out mice; glucagon; glucagon-like peptide-1; glucose tolerance; liraglutide; obesity; type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; REDUCES BODY-WEIGHT; FOOD-INTAKE; GLYCEMIC CONTROL; CARDIOVASCULAR RISK; ENERGY-EXPENDITURE; CLINICAL-TRIAL; GLP-1; ANALOG; INSULIN; OXYNTOMODULIN;

D O I：

10.1111/dom.12735

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AimsTo characterize the pharmacology of MEDI0382, a peptide dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. Materials and methods MEDI0382 was evaluated in vitro for its ability to stimulate cAMP accumulation in cell lines expressing transfected recombinant or endogenous GLP-1 or glucagon receptors, to potentiate glucose-stimulated insulin secretion (GSIS) in pancreatic -cell lines and stimulate hepatic glucose output (HGO) by primary hepatocytes. The ability of MEDI0382 to reduce body weight and improve energy balance (i.e. food intake and energy expenditure), as well as control blood glucose, was evaluated in mouse models of obesity and healthy cynomolgus monkeys following single and repeated daily subcutaneous administration for up to 2months. Results MEDI0382 potently activated rodent, cynomolgus and human GLP-1 and glucagon receptors and exhibited a fivefold bias for activation of GLP-1 receptor versus the glucagon receptor. MEDI0382 produced superior weight loss and comparable glucose lowering to the GLP-1 peptide analogue liraglutide when administered daily at comparable doses in DIO mice. The additional fat mass reduction elicited by MEDI0382 probably results from a glucagon receptor-mediated increase in energy expenditure, whereas food intake suppression results from activation of the GLP-1 receptor. Notably, the significant weight loss elicited by MEDI0382 in DIO mice was recapitulated in cynomolgus monkeys. ConclusionsRepeated administration of MEDI0382 elicits profound weight loss in DIO mice and non-human primates, produces robust glucose control and reduces hepatic fat content and fasting insulin and glucose levels. The balance of activities at the GLP-1 and glucagon receptors is considered to be optimal for achieving weight and glucose control in overweight or obese Type 2 diabetic patients.

引用

页码：1176 / 1190

页数：15